Literature DB >> 12828498

Pain in terminally ill patients: guidelines for pharmacological management.

Jay R Thomas1, Charles F von Gunten.   

Abstract

Successful pharmacological treatment of pain in terminally ill patients is possible most of the time. It requires a determination of the type of pain syndrome (i.e. nociceptive, neuropathic or mixed). Complete pain assessment also requires an understanding of other dimensions of suffering that a patient may be experiencing on psychological, social and spiritual/existential levels. The World Health Organization has introduced a three-step approach to treating pain. Opioids are the mainstay of therapy for moderate to severe pain at the end of life. Familiarity with the pharmacokinetics, equianalgesic dose and adverse effects of opioids is necessary for their safe and effective use. In addition, adjuvant analgesics such as antiepileptic drugs, antidepressants and local anaesthetics are often needed to optimise pain control, especially in patients with neuropathic pain. Given the complex aetiology of pain states, combinations of classes of adjuvants may sometimes be needed for effective treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828498     DOI: 10.2165/00023210-200317090-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  56 in total

Review 1.  Pharmacology of corticosteroids.

Authors:  P Demoly; K F Chung
Journal:  Respir Med       Date:  1998-03       Impact factor: 3.415

Review 2.  Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration.

Authors:  M P Davis; D Walsh
Journal:  Support Care Cancer       Date:  2001-03       Impact factor: 3.603

3.  The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.

Authors:  X Du; G Skopp; R Aderjan
Journal:  Ther Drug Monit       Date:  1999-04       Impact factor: 3.681

4.  Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators.

Authors:  Antonio Vigano'; David Fan; Eduardo Bruera
Journal:  Pain       Date:  1996-09       Impact factor: 6.961

Review 5.  The spinal pharmacology of facilitation of afferent processing evoked by high-threshold afferent input of the postinjury pain state.

Authors:  T L Yaksh
Journal:  Curr Opin Neurol Neurosurg       Date:  1993-04

6.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Authors:  M B Max; S A Lynch; J Muir; S E Shoaf; B Smoller; R Dubner
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

7.  Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study.

Authors:  B S Galer; J Harle; M C Rowbotham
Journal:  J Pain Symptom Manage       Date:  1996-09       Impact factor: 3.612

Review 8.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

9.  Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.

Authors:  R B Raffa; E Friderichs; W Reimann; R P Shank; E E Codd; J L Vaught
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

10.  Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats.

Authors:  J C Eisenach; G F Gebhart
Journal:  Anesthesiology       Date:  1995-11       Impact factor: 7.892

View more
  2 in total

Review 1.  Management of pain in the elderly at the end of life.

Authors:  Eric Prommer; Brandy Ficek
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

Review 2.  The challenges of cancer pain assessment and management.

Authors:  Victoria Campbell
Journal:  Ulster Med J       Date:  2011-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.